Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2143)	1/22/2008 9:59:48 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

MITI Is up 31% in spite of the general market.<g> stockcharts.com It announced today the publication of a preclinical study in Cancer Research demonstrating that efficacious doses of an antibody targeting epithelial cell adhesion molecule were well tolerated in two mouse cancer models. MITI's BiTE antibodies join with T cells,aiming for a controlled elimination of Ca. cells. MITI has been trimming its losses in the last 2Qs & the revenues in the last Q were up 20%, but the losses for 2007 & 2008 are still expected to be at the same level as in 2006 The stock needs to close above its resistance at the $2 level.<g> stockcharts.com Bernard